| EW |
Report |
2Q26 total sales |
BEAT |
pred ~$1.72B vs. cons $1.70B |
MEDIUM |
| EW |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$0.77 vs. cons $0.74 |
MEDIUM |
| EW |
Report |
2Q26 TAVR sales |
IN-LINE |
pred ~$1.24B vs. cons $1.23B |
MEDIUM |
| EW |
Guide |
FY26 total-sales guidance midpoint |
LOWER |
guide ~$6.70B vs. cons $6.73B (FY26) |
MEDIUM |
| EW |
Guide |
FY26 adjusted-EPS guidance midpoint |
LOWER |
guide ~$3.00 vs. cons $3.02 (FY26) |
MEDIUM |
| EW |
Guide |
FY26 TAVR constant-currency growth guidance midpoint |
LOWER |
guide ~8.0% vs. cons 8.5% (FY26) |
MEDIUM |
| EW |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| EW |
Return |
5-day cumulative residual |
-5.5% (FOLLOW-THROUGH) |
A ~$1.72B sales print and ~$0.77 EPS beat versus $1.70B and $0.74 consensus are likely outweighed by a ~$6.70B FY26 revenue midpoint versus $6.73B consensus and ~$3.00 EPS midpoint versus $3.02, implying modest out-period estimate cuts as tougher 2H TAVR comparisons remain the central concern. |
MEDIUM |